INTRODUCTION

Patients with moderate plaque psoriasis (i.e., 5% to 10% psoriasis-involved body surface area [BSA])

Efficacy and Safety of Plaque Psoriasis (Psoriasis Area and Severity Index).

RESULTS

Figure 4. Mean Percentage Change in PASI at Baseline, Week 16, and Week 52

Figure 5. Mean Percentage Change in PGAxBSA at Baseline, Week 16, and Week 52

Table 3. Overview of Adverse Events

Table 4. Mean Percentage Change in PGAxBSA at Baseline, Week 16, and Week 52

RESULTS (cont’d)

Figure 6. Apremilast 30 mg BID

RESULTS (cont’d)

Table 2. Overview of Adverse Events

Table 5. Mean Percentage Change in DLQI Total Score at Baseline, Week 16, and Week 52

METHODS

METHODS (cont’d)

RESULTS (cont’d)

EFICACIES

RESULTS (cont’d)

CONCLUSIONS

REFERENCES

ACKNOWLEDGMENTS

DISCLOSURES